Main Street Financial Solutions LLC Invests $3.45 Million in Merck & Co., Inc. $MRK

Main Street Financial Solutions LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 26,862 shares of the company’s stock, valued at approximately $3,452,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC grew its position in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC lifted its position in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after purchasing an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC boosted its stake in shares of Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after purchasing an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after purchasing an additional 359,356 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the subject of a number of research reports. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a research report on Wednesday, August 12th. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Wolfe Research increased their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Wells Fargo & Company lifted their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $147.60.

Insider Buying and Selling

In other news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares in the company, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Michael Williams sold 52,847 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. This trade represents a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last 90 days. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Trading Down 2.1%

NYSE MRK opened at $153.21 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The stock has a market capitalization of $378.00 billion, a PE ratio of 122.57, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19. The firm has a 50 day moving average of $130.39 and a two-hundred day moving average of $122.04.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.